Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: 2 | Vintage Vibes

2 'Strong Buy' Biotech Stocks With 120% or More Upside Potential

With the growing demand for cutting-edge therapies reshaping the healthcare landscape, here are two “Strong Buy”-rated biotech stocks with significant potential upside.

Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data

Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.

Up 285% YTD, Is It Too Late to Buy This Biotech Stock?

Up 285% YTD, Is It Too Late to Buy This Biotech Stock?

Viking Therapeutics is making notable advancements in obesity treatment with VK2735 and exploring strategic partnerships for its NASH program, positioning itself at the forefront of metabolic and endocrine disorder therapies

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

Structure Therapeutics vs. Viking Therapeutics: Which Weight-Loss Drug Stock Wins?

With weight-loss drugs gaining traction, which biopharma stock wins?

Investors Beware of These 3 Pharma Stocks

Rising costs, regulatory hurdles, and cyberattacks are some of the challenges that the pharmaceutical industry faces. Although the sector looks well-positioned for growth, not all pharma stocks would be able to capitalize on the industry trends. Therefore, investors should look to avoid fundamentally weak pharma stocks: Madrigal Pharmaceuticals (MDGL), Viking…

This Small-Cap Biotech Could Gain Over 165%, Says Wall Street

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to combat obesity. Is TERN stock a good buy right now?

inkl

Read news from The Economist, FT, and more,
with one subscription

Up 283% YTD, Is It Too Late to Buy Viking Therapeutics Stock?

Up 283% YTD, Is It Too Late to Buy Viking Therapeutics Stock?

Shares of Viking Therapeutics have been on an absolute tear in 2024, as the biotech stock gears up to enter the weight-loss drug market.

Viking Therapeutics Earnings Preview

Viking Therapeutics Earnings Preview

Viking Therapeutics (NASDAQ:VKTX) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Viking Therapeutics will report an earnings per share (EPS) of $-0.19.

Viking Therapeutics: Q4 Earnings Insights

Viking Therapeutics: Q4 Earnings Insights

Viking Therapeutics (NASDAQ:VKTX) reported its Q4 earnings results on Wednesday, February 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Medical Pharmaceuticals

Viking Therapeutics

Viking Therapeutics Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play